Oppenheimer on July 24 raised the firm’s price target on Boston Scientific (BSX) to $118 from $110 and kept a Perform rating on the shares. The firm updated the company’s model post the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Insider Moves: Charles Schwab, Phillips 66, NXP, Corning, Boston Scientific
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Positive Outlook for Boston Scientific Driven by Strong Growth Strategy and Leadership in Key Segments
- Boston Scientific price target raised to $125 from $120 at RBC Capital
- Boston Scientific price target raised to $118 from $110 at Oppenheimer